CA2267193A1 - Compositions therapeutiques et procedes de traitement de maladies utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1), le facteur inhibiteur des colonies de monocytes (m-cif) et le facteur-4 inhibiteur de la migration des macrophages (mip-4) - Google Patents

Compositions therapeutiques et procedes de traitement de maladies utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1), le facteur inhibiteur des colonies de monocytes (m-cif) et le facteur-4 inhibiteur de la migration des macrophages (mip-4) Download PDF

Info

Publication number
CA2267193A1
CA2267193A1 CA002267193A CA2267193A CA2267193A1 CA 2267193 A1 CA2267193 A1 CA 2267193A1 CA 002267193 A CA002267193 A CA 002267193A CA 2267193 A CA2267193 A CA 2267193A CA 2267193 A1 CA2267193 A1 CA 2267193A1
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
polypeptide
mpif
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002267193A
Other languages
English (en)
Inventor
Reiner L. Gentz
Vikram Patel
Brent L. Kreider
Jun Zhang
Michael Antonaccio
Donna Mendrick
Pablo Jimenez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2267193A1 publication Critical patent/CA2267193A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à des compositions thérapeutiques et à des procédés utilisant des molécules d'acides nucléiques isolées codant un polypeptide du facteur-1 inhibiteur des précurseurs myéloïdes (MPIF-1) d'origine humaine (précédemment appelé MIP-3 et chimiokine .beta.8 (CK.beta.8 ou ckb-8)); un polypeptide du facteur inhibiteur des colonies de monocytes (M-CIF) d'origine humaine (précédemment appelé MIP1-.gamma. et chimiokine .beta.1(CK.beta.1 ou ckb-1)), et une protéine inhibant la migration des macrophages (MIP-4). L'invention se rapporte également aux polypeptides de MPIF-1, M-CIF et/ou MIP-4 ainsi qu'à des vecteurs, cellules hôtes et procédés de recombinaison destinés à la production desdits polypeptides.
CA002267193A 1996-09-30 1997-09-30 Compositions therapeutiques et procedes de traitement de maladies utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1), le facteur inhibiteur des colonies de monocytes (m-cif) et le facteur-4 inhibiteur de la migration des macrophages (mip-4) Abandoned CA2267193A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2730096P 1996-09-30 1996-09-30
US2729996P 1996-09-30 1996-09-30
US60/027,299 1996-09-30
US60/027,300 1996-09-30
PCT/US1997/017505 WO1998014582A1 (fr) 1996-09-30 1997-09-30 Compositions therapeutiques et procedes de traitement de maladies utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1), le facteur inhibiteur des colonies de monocytes (m-cif) et le facteur-4 inhibiteur de la migration des macrophages (mip-4)

Publications (1)

Publication Number Publication Date
CA2267193A1 true CA2267193A1 (fr) 1998-04-09

Family

ID=26702293

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002267193A Abandoned CA2267193A1 (fr) 1996-09-30 1997-09-30 Compositions therapeutiques et procedes de traitement de maladies utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1), le facteur inhibiteur des colonies de monocytes (m-cif) et le facteur-4 inhibiteur de la migration des macrophages (mip-4)

Country Status (8)

Country Link
EP (1) EP0941330A1 (fr)
JP (1) JP2001500382A (fr)
KR (1) KR20030097607A (fr)
CN (1) CN1239510A (fr)
AU (1) AU4657697A (fr)
CA (1) CA2267193A1 (fr)
NZ (2) NZ506135A (fr)
WO (1) WO1998014582A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US6623942B2 (en) 1994-03-08 2003-09-23 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polynucleotides
AU775308B2 (en) * 1996-09-30 2004-07-29 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
WO2000028035A1 (fr) 1998-11-10 2000-05-18 Human Genome Sciences Inc. CHEMOKINE β-7
EP1142908A4 (fr) * 1999-01-07 2002-05-22 Takeda Chemical Industries Ltd Procede de production de proteines activees
WO2001026676A1 (fr) * 1999-10-14 2001-04-19 Human Genome Sciences, Inc. Methodes de traitement ou de prevention de lesions des cellules, des tissus et des organes utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1) d'origine humaine
EP1176200A3 (fr) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Utilisation des polypeptides ou leurs acides nucléiques pour le diagnose ou traitement des maladies de la peau ou de la cicatrisation de blessures et leurs utilisations pour l'identification des substances pharmacologiquement actives
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
KR100867257B1 (ko) * 2001-10-09 2008-11-11 케모센트릭스, 인크. 포밀 펩티드 수용체 유사 1 수용체에 대한 리간드로유용한 조성물 및 이의 사용 방법
AU2004283853A1 (en) * 2003-10-24 2005-05-06 Tap Pharmaceutical Products Inc. Human chemokine HCC-1 polypeptides to improve stem cell transplantation
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
BRPI0509033A (pt) * 2004-03-22 2007-08-07 Novartis Ag ferramenta diagnóstica
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
JP5272011B2 (ja) * 2007-10-22 2013-08-28 セントビンセンツ ホスピタル シドニー リミテッド 予後判定の方法
CN113215085B (zh) * 2021-05-07 2024-05-10 澳门大学 一种脂类物质添加剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143894A (zh) * 1993-12-22 1997-02-26 人类基因组科学公司 巨噬细胞炎性蛋白-3，-4和-1r
DE59410132D1 (de) * 1993-12-24 2002-07-11 Forssmann Wolf Georg Humanes zirkulierendes cytokin cc-1
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
MX9708537A (es) * 1995-05-05 1998-02-28 Human Genome Sciences Inc Quimiocina beta-8 quimiocina beta-1 y proteina-4 inflamatoria de los macrofagos, humanas.
EA199800352A1 (ru) * 1995-09-29 1998-12-24 Смитклайн Бичам Корпорейшн ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
WO1997015594A1 (fr) * 1995-10-24 1997-05-01 Smithkline Beecham Corporation Nouvelles chimiokines utilisees pour mobiliser des cellules souches

Also Published As

Publication number Publication date
EP0941330A1 (fr) 1999-09-15
AU4657697A (en) 1998-04-24
NZ506135A (en) 2002-11-26
CN1239510A (zh) 1999-12-22
NZ335003A (en) 2000-11-24
JP2001500382A (ja) 2001-01-16
WO1998014582A1 (fr) 1998-04-09
KR20030097607A (ko) 2003-12-31

Similar Documents

Publication Publication Date Title
US7851596B2 (en) Myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides
US6372454B2 (en) Nucleic acid molecules encoding Follistatin-3
US6608182B1 (en) Human vascular endothelial growth factor 2
CA2267193A1 (fr) Compositions therapeutiques et procedes de traitement de maladies utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1), le facteur inhibiteur des colonies de monocytes (m-cif) et le facteur-4 inhibiteur de la migration des macrophages (mip-4)
US6001606A (en) Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
JP2003102486A (ja) ヒトケモカインベータ−８、ケモカインベータ−１、およびマクロファ−ジ炎症性タンパク質−４
EP1012260A1 (fr) Interleukine-20
WO1998014582A9 (fr) Compositions therapeutiques et procedes de traitement de maladies utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1), le facteur inhibiteur des colonies de monocytes (m-cif) et le facteur-4 inhibiteur de la migration des macrophages (mip-4)
US6623942B2 (en) Macrophage inflammatory protein-4 (MIP-4) polynucleotides
US6488925B2 (en) Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6379926B1 (en) Polynucleotides encoding chemokine β-6 antagonists
US6485719B1 (en) Methods for inhibiting angiogenesis with leukocyte adhesion inhibitor-1 (LAI-1) polypeptides
EP1036164B1 (fr) Chemokine alpha-5
US20030147846A1 (en) Methods of using macrophage inflammatory protein-4 (MIP-4) and myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides
AU777297B2 (en) Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
KR20000048743A (ko) 골수양 선조 세포 억제 인자-1(ｍｐｉｆ-1), 단핵구 콜로니 억제인자(ｍ-ｃｉｆ) 및 대식 세포 억제 인자-4(ｍｉｐ-4)를이용하여질병 상태를 치료하기 위한 치료 조성물 및 치료 방법
WO2001030828A1 (fr) Compositions therapeutiques et techniques de traitement d'etats pathologiques avec des formes mutantes du facteur-2 inhibiteur des precurseurs myeloides (mpif-2)
CA2413012A1 (fr) Facteur de croissance endotheliale vasculaire 2 humain

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead